"Organovo (NYSE: ONVO) 19.4% HIGHER; entered into a multi-year research collaboration agreement with Merck Sharp & Dohme Corp. (MRK). The Agreement will give Merck access to Organovo?s commercial exVive3DTM Human Liver Tissue service, and will also involve a collaboration to develop multiple custom tissue models utilizing the Company?s proprietary NovoGen Bioprinting PlatformTM, for use in drug development."
|